MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 136, Issue 12, Pages 2844-2853
Publisher
Wiley
Online
2014-11-15
DOI
10.1002/ijc.29332
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation
- (2013) F. Pietrantonio et al. ANNALS OF ONCOLOGY
- Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
- (2013) Alexander M. Menzies et al. EUROPEAN JOURNAL OF CANCER
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
- (2013) Mark R. Gilbert et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of MGMT Testing in Clinical Practice
- (2013) Milena Cankovic et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy
- (2013) M. Weiler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic significance of MGMT gene promoter methylation in differently treated metastatic melanomas
- (2012) A.M. Cesinaro et al. PATHOLOGY
- A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts
- (2011) Deborah S. Malley et al. ACTA NEUROPATHOLOGICA
- Quantitative miRNA Expression Analysis Using Fluidigm Microfluidics Dynamic Arrays
- (2011) Jin Sung Jang et al. BMC GENOMICS
- Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas
- (2011) Jörg Felsberg et al. INTERNATIONAL JOURNAL OF CANCER
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
- (2010) J C Hassel et al. BRITISH JOURNAL OF CANCER
- MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC
- (2010) Christian Busch et al. EUROPEAN JOURNAL OF CANCER
- Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial
- (2010) Ewa Wierzbicka-Hainaut et al. MELANOMA RESEARCH
- Long-Term Survival in Patients with Metastatic Melanoma Treated with DTIC or Temozolomide
- (2010) C. Kim et al. ONCOLOGIST
- Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation WithMGMTPromoter Methylation Status
- (2009) Alba A. Brandes et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- High Throughput Gene Expression Measurement with Real Time PCR in a Microfluidic Dynamic Array
- (2008) Sandra L. Spurgeon et al. PLoS One
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search